Erasca Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$ERAS
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ERAS alert in real time by email
8-K
0001761918false00017619182024-11-122024-11-12

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2024

 

 

Erasca, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40602

83-1217027

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

3115 Merryfield Row

Suite 300

 

San Diego, California

 

92121

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (858) 465-6511

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

ERAS

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 2.02 Results of Operations and Financial Condition.

On November 12, 2024, Erasca, Inc. announced its financial results for the three months ended September 30, 2024. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

 

Exhibit Description

99.1 Press Release issued November 12, 2024

104 Cover Page Interactive Data File


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Erasca, Inc.

 

 

 

 

Date:

November 12, 2024

By:

/s/ Ebun Garner

 

 

 

General Counsel

 


Get the next $ERAS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ERAS

DatePrice TargetRatingAnalyst
3/26/2025$5.00Outperform
Raymond James
11/18/2024$6.00Buy
Jefferies
3/11/2024$8.00Overweight
CapitalOne
1/5/2024$11.00 → $6.00Buy → Neutral
BofA Securities
10/11/2023$10.00Buy
H.C. Wainwright
3/30/2023$9.00Buy
Mizuho
2/24/2023$10.00Buy
Goldman
2/3/2023$15.00Equal-Weight → Overweight
Morgan Stanley
More analyst ratings

$ERAS
Press Releases

Fastest customizable press release news feed in the world

See more
  • Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting

    Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Erasca will also present potential first-in-class examples of direct SMP complex inhibitors, representing a new approach to block the RAS/MAPK pathway SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the company will present three poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 25 - 30, 2025,

    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results

    Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3 SEACRAFT-2 registrational trial progressing well with Stage 1 randomized data expected in H2 2025 Robust balance sheet with cash, cash equivalents, and marketable securities of $440 million as of December 31, 2024 is expected to fund operations into H2 2027 SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported

    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

    SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Securities SMID Cap Biotech Conference being held at the Lotte New York Palace in New York, New York. Management will participate in a fireside chat on Thursday, February 6, 2025, at 9:30 am Eastern Time and will also participate in one-on-one investor meetings. A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30

    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ERAS
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ERAS
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ERAS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ERAS
SEC Filings

See more

$ERAS
Leadership Updates

Live Leadership Updates

See more
  • Erasca Appoints Jean Liu to its Board of Directors

    SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Jean Liu to its board of directors and to its audit committee. Ms. Liu brings over 20 years of professional experience advising biopharmaceutical companies on corporate, intellectual property, compliance, and general legal matters. "Jean Liu has been a seasoned executive with Seagen during its transformation into a leading global, multiproduct oncology company, and she also is one of the most strategic busine

    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Erasca Strengthens Leadership Team with Two Key Executive Appointments

    Lisa Tesvich-Bonora appointed as Chief People Officer Robert Shoemaker promoted to Senior Vice President of Research SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Lisa Tesvich-Bonora as Chief People Officer and the promotion of Robert Shoemaker to Senior Vice President of Research. "I am thrilled to welcome Lisa to the Erasca family. With over two decades of experience in creating collaborative and engaging environments where employees can thrive, she bring

    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ERAS
Financials

Live finance-specific insights

See more
  • Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

    Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors Pipeline prioritization and workforce restructuring sharpens focus on programs targeting the highest unmet needs and with highest probability of success Priced concurrent $160 million equity offering Erasca to host conference call and webcast Friday, May 17, 2024 at 8:30 am ET SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today anno

    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Erasca Reports First Quarter 2024 Business Updates and Financial Results

    Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma Strengthened balance sheet with private placement financing from high-quality new and existing healthcare-focused investors Pro forma cash, cash equivalents, and marketable securities of $334 million is expected to fund operations into H2 2026 SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended March

    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

    Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts expected in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES-3), and ERAS-801 (THUNDERBBOLT-1) and planned initiation of pivotal SEACRAFT-2 trial Robust balance sheet with cash, cash equivalents, and marketable securities of $322 million as of December 31, 2023 Erasca to host R&D update conference call and webcast Thursday, March 28, 2024 at 8:30 am ET SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and comm

    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ERAS
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more